Literature DB >> 11464874

Observation of untreated patients with neuroblastoma detected by mass screening: a "wait and see" pilot study.

A Yoneda1, T Oue, K Imura, M Inoue, K Yagi, K Kawa, M Nishikawa, S Morimoto, M Nakayama.   

Abstract

BACKGROUND: Recent studies have indicated that mass screening for neuroblastoma detects tumors that otherwise would have regressed spontaneously without recognition. Therefore, we started an observation program for these patients to determine how frequently spontaneous regression occurs. PROCEDURE: Eighteen patients were detected by mass screening between June 1994 and December 1996. Eight of these cases matched the following criteria and entered the observation program: Stage I or II, less than 5 cm in diameter; no involvement of large vessels or organs; not difficult to resect; informed consent. If there were an increase in tumor size, an elevation of tumor markers, or evidence of metastasis, the tumor would be immediately resected.
RESULTS: Five of the eight cases showed spontaneous regression. Although the remaining three tumors were resected 6-10 months after diagnosis, all patients survived without evidence of recurrence.
CONCLUSIONS: At least 60% of neuroblastoma cases who entered our observation program regressed spontaneously.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11464874     DOI: 10.1002/1096-911X(20010101)36:1<160::AID-MPO1039>3.0.CO;2-G

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  9 in total

Review 1.  The role of surgery in the treatment of neuroblastoma.

Authors:  Masayuki Kubota
Journal:  Surg Today       Date:  2010-05-23       Impact factor: 2.549

2.  A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study.

Authors:  Jed G Nuchtern; Wendy B London; Carol E Barnewolt; Arlene Naranjo; Patrick W McGrady; James D Geiger; Lisa Diller; Mary Lou Schmidt; John M Maris; Susan L Cohn; Robert C Shamberger
Journal:  Ann Surg       Date:  2012-10       Impact factor: 12.969

3.  Can neoadjuvant chemotherapy reduce the surgical risks for localized neuroblastoma patients with image-defined risk factors at the time of diagnosis?

Authors:  Akihiro Yoneda; Masanori Nishikawa; Shuichiro Uehara; Takaharu Oue; Noriaki Usui; Masami Inoue; Masahiro Fukuzawa; Hiroomi Okuyama
Journal:  Pediatr Surg Int       Date:  2016-01-13       Impact factor: 1.827

4.  Long-term follow-up of the "wait and see" approach to localized perinatal adrenal neuroblastoma.

Authors:  Denis Andrew Cozzi; Ermelinda Mele; Silvia Ceccanti; Fabio Natale; Anna Clerico; Amalia Schiavetti; Carlo Dominici
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

5.  Retrospective study of neuroblastoma in Chinese neonates from 1994 to 2011: an evaluation of diagnosis, treatments, and prognosis : a 10-year restrospective study of neonatal neuroblastoma.

Authors:  Yaodong Zhou; Kai Li; Shan Zheng; Lian Chen
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-05       Impact factor: 4.553

6.  Suprarenal Masses in Very Young Infants: Is It Safe to Watch and Wait? Report of a SIOPEN Observational Study Results.

Authors:  Vassilios Papadakis; Vanessa Segura; Massimo Conte; Dominique Plantaz; Andrea Di Cataldo; Gudrun Schleiermacher; Kate Wheeler; Jose D Bermúdez; Shifra Ash; Bénédicte Brichard; Ruth Ladenstein; Valérie Combaret; Sabine Sarnacki; Anna Maria Fagnani; Claudio Granata; Adela Cañete
Journal:  Cancers (Basel)       Date:  2022-08-19       Impact factor: 6.575

7.  PPARgamma in Neuroblastoma.

Authors:  Alessandro Peri; Ilaria Cellai; Susanna Benvenuti; Paola Luciani; Silvana Baglioni; Mario Serio
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

8.  Secular trends in neuroblastoma mortality before and after the cessation of national mass screening in Japan.

Authors:  Kota Katanoda; Kunihiko Hayashi; Keiko Yamamoto; Tomotaka Sobue
Journal:  J Epidemiol       Date:  2009-08-01       Impact factor: 3.211

9.  Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.

Authors:  Shigeki Yagyu; Tomoko Iehara; Shiro Tanaka; Takahiro Gotoh; Akiko Misawa-Furihata; Tohru Sugimoto; Wendy B London; Michael D Hogarty; Satoshi Teramukai; Akira Nakagawara; Eiso Hiyama; John M Maris; Hajime Hosoi
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.